Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00193
|
|||||
Drug Name |
Tamoxifen
|
|||||
Synonyms |
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Citofen; Crisafeno; Diemon; Gen-Tamoxifen; Istubal (TN); Istubol; Nolvadex (TN); Nolvadex-D; Nourytam; Novaldex; Novo-Tamoxifen; Oncomox; Pms-Tamoxifen; Retaxim; TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); TRANS FORM OF TAMOXIFEN; Tamizam; Tamone; Tamoplex (TN); Tamoxen; Tamoxifen (Hormonal therapy); Tamoxifen (INN); Tamoxifen (TN); Tamoxifen (Z); Tamoxifen [INN:BAN]; Tamoxifen and its salts; Tamoxifene; Tamoxifene [INN-French]; Tamoxifeno [INN-Spanish]; Tamoxifeno;Tamoxifenum; Tamoxifenum [INN-Latin]; Tomaxithen; Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; Trans-Tamoxifen; Valodex; Valodex (TN)
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Breast cancer [ICD11: 2C60-2C6Z] | Approved | [1] | |||
Therapeutic Class |
Anticancer Agents
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C26H29NO
|
|||||
Canonical SMILES |
CCC(=C(C1=CC=CC=C1)C2=CC=C(C=C2)OCCN(C)C)C3=CC=CC=C3
|
|||||
InChI |
InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
|
|||||
InChIKey |
NKANXQFJJICGDU-QPLCGJKRSA-N
|
|||||
CAS Number |
CAS 10540-29-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 371.5 | Topological Polar Surface Area | 12.5 | ||
Heavy Atom Count | 28 | Rotatable Bond Count | 8 | |||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 2 | |||
XLogP |
7.1
|
|||||
PubChem CID | ||||||
PubChem SID |
11113844
, 14853108
, 24900307
, 26697206
, 26752017
, 26752018
, 30091348
, 4266414
, 46393636
, 46487938
, 46505515
, 47213210
, 47216564
, 47364953
, 47364954
, 47364955
, 47588786
, 47662047
, 47662048
, 47662049
, 47736233
, 47959503
, 48184778
, 48258990
, 48334237
, 48427434
, 49688681
, 49698369
, 49854602
, 50104683
, 50104684
, 50104685
, 50104686
, 53789476
, 56310641
, 56310662
, 56310717
, 56310801
, 56311275
, 56311294
, 56311693
, 56311998
, 56312239
, 56312443
, 56312444
, 603542
, 7886804
, 7980727
, 8794645
, 9319
|
|||||
ChEBI ID |
ChEBI:41774
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
MRP7 | Transporter Info | Multidrug resistance-associated protein 7 | Substrate | [3] | ||
P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [4] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | MRP7 | Transporter Info | Km = 0.078 microM | LLC-PK1 cells-MRP7 | [3] | |
References | ||||||
1 | Tamoxifen was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72. | |||||
3 | Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67. | |||||
4 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.